Regensburg, August 10, 2016. The supervisory board of numares AG has appointed Dr. Titus Kaletta (47) as a member of the executive board effective July 1, 2016. His main responsibility will be to further develop sales throughout Europe and Asia.
 

Kaletta holds a doctoral degree in biochemistry and worked for various international life science companies in different managerial positions, before joining numares in the spring of 2016. His previous positions focused on market positioning and business development.
 

"In Titus Kaletta, we have acquired a highly dedicated manager who possesses several years of experience in the life science industry. Thanks to his scientific and economic expertise, he will provide us with decisive support for the further expansion of our sales activities. Titus Kaletta's new position is an expression of our uninterrupted growth rate and we are currently creating the structures required for this development. At the beginning of the year, we entered a partnership with Limbach, the leading laboratory group in Germany, to conduct lipoprotein tests. This represents an important step for tapping into new markets," explains Dr. Volker Pfahlert, CEO of numares AG.
 

"I am very excited about my new role. numares has great potential to gain additional customers for its innovative and cost-effective technology. Furthermore, numares test systems have proven to be reliable, resilient and reproducible and have already been incorporated into various application areas as part of the daily clinical routine. This has formed a solid basis, which we will now use to approach others involved in the fields of diagnostics, clinical research and science throughout Europe and Asia," explains Dr. Titus Kaletta, executive board member of numares AG.
 

For a photo of numares-COO Dr. Titus Kaletta, please click here.
 

About numares:
 

numares is a specialized developer and provider of analytic and diagnostic test systems based on nuclear magnetic resonance (NMR) spectroscopy and numares' proprietary Magnetic Group Signaling (MGS) technology.

numares HEALTH develops and markets in-vitro diagnostic tests with the CE-marking and integrated test systems for high-throughput use in clinical diagnostics and life science research. The highly standardized tests provide valuable information on the disease status of patients in the indication areas of cardiovascular disease, nephrology and oncology.

In addition, numares HEALTH provides its test systems to the pharmaceutical industry on a fee-for-service basis. They can be used for example to investigate the therapeutic effects of medication as part of clinical trials. Furthermore, the company supports customers with complex issues and clinical trials, drawing on its many years of expertise and experience in the area of NMR spectroscopy and metabolomics.

www.numares.com
 

Media contact:

numares AG
Dipl.-Biol. Christiane Proll, MBA
Tel.: +49 941 2809 49-14
E-mail: christiane.proll@numares.com
 

IRA WÜLFING KOMMUNIKATION GmbH
Dr. Reinhard Saller
Tel.: +49 89 2000 30-30
E-mail: reinhard.saller@wuelfing-kommunikation.de